Vorinostat

A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.

Also Known As:

18F-SAHA; 18F-Suberoylanilide Hydroxamic Acid; M344; MK-0683; MK0683; N-Hydroxy-N'-phenyloctanediamide; N1-Hydroxy-N8-phenyloctanediamide; NHNPODA; Suberanilohydroxamic Acid; Suberoyl Anilide Hydroxamic Acid; Suberoylanilide Hydroxamic Acid; Zolinza; 18F Suberoylanilide Hydroxamic Acid; MK 0683; N Hydroxy N' phenyloctanediamide; N1 Hydroxy N8 phenyloctanediamide

Networked: 1523 relevant articles (119 outcomes, 402 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133

Experts

1.	Grant, Steven: 27 articles (01/2018 - 12/2003)
2.	Richon, Victoria M: 24 articles (07/2015 - 05/2002)
3.	Marks, Paul A: 23 articles (04/2012 - 05/2002)
4.	Dent, Paul: 21 articles (01/2020 - 12/2003)
5.	Espinoza-Delgado, Igor: 17 articles (01/2015 - 04/2009)
6.	Alam, Hasan B: 12 articles (04/2015 - 11/2009)
7.	Li, Yongqing: 12 articles (04/2015 - 11/2009)
8.	Liu, Baoling: 12 articles (04/2015 - 11/2009)
9.	Duvic, Madeleine: 11 articles (01/2021 - 11/2005)
10.	Reid, Joel M: 10 articles (01/2018 - 04/2009)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "We also examined the efficacy of vorinostat in a patient-derived xenograft (PDX) model developed using tumor tissue obtained from the patient's most recent tumor resection. " 01/01/2009 - "Suberoylanilide hydroxamic acid (SAHA) is effective against many cancer cells and functions by up-regulating an endogenous inhibitor of Trx. " 02/01/2013 - "In this study, we evaluated the safety, pharmacokinetics, and efficacy of two dosing regimens of vorinostat, an oral HDACi, in patients with GI tumors. " 01/01/2020 - "Genetic ablation of xCT improved the efficacy of vorinostat, consistent with the results of public data analyses demonstrating that xCT expressions positively correlate with insensitivity to HDACIs in many types of cancer cell lines. " 01/01/2015 - "However, vorinostat-NPs showed improved antitumor activity against HuCC-T1 cancer cell-bearing mice compared to vorinostat, whereas empty nanoparticles had no effect on tumor growth. "
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 05/15/2020 - "Vorinostat has good therapeutic efficacy against primary cutaneous T-cell lymphoma in the refractory stage. " 05/15/2015 - "Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors." 10/14/2010 - "Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi and other agents have been actively tested in many clinical trials. " 05/01/2008 - "A large number of these agents that have different chemical structures and can target multiple HDACs are being testing in clinical trials and vorinostat is now an approved drug for the treatment of cutaneous T-cell lymphoma. " 06/01/2007 - "A well-known HDACi, suberoylanilide hydroxamic acid, has been recently approved for the treatment of cutaneous T cell lymphoma, and a number of HDACi are in clinical trials as anticancer drugs. "
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/01/2009 - "Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically. " 10/01/2009 - "A phase 2 study of vorinostat in acute myeloid leukemia." 10/01/2009 - "Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia. " 06/01/2013 - "Finally, the MK-8776/vorinostat regimen was active in primary acute myelogenous leukemia (AML) blasts, particularly against the CD34(+)/CD38(-)/CD123(+) population enriched for leukemia-initiating cells. " 02/01/2011 - "Vorinostat in acute myeloid leukemia and myelodysplastic syndromes."
4.	Leukemia 01/01/2022 - "Our results suggest a lack of benefit from adding a short course of vorinostat to i.v. Bu/Flu/Clo conditioning regimens for leukemia patients undergoing allo- HSCT." 01/01/2015 - "Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells." 06/01/2013 - "Leukemia cell lines carrying FLT3-ITD were also sensitive to the MK-8776/vorinostat regimen. " 04/01/2013 - "No differences in percentage S-phase cells or multidrug resistance transporter (MDR1 or BCRP) expression or function were observed in vivo in leukemia blasts upon vorinostat treatment. " 08/01/2010 - "Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells."
5.	Lymphoma (Lymphomas) 04/01/2015 - "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. " 04/01/2015 - "A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma." 01/01/2014 - "Clinical trials have led to approval of SAHA (Vorinostat) for treatment of lymphoma. " 01/01/2010 - "A phase I trial of oral vorinostat was conducted in Japanese patients with malignant lymphoma. " 08/26/2021 - "In leukemic cell line MV4-11 and in the lymphoma cell line Daudi, three compounds showed lower IC50 values than Vorinostat. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Vorinostat
3.	Histone Deacetylases (Histone Deacetylase)
4.	trichostatin A (A 300)
5.	Valproic Acid (Depakote)
6.	Bortezomib (Velcade)
7.	Histones (Histone)
8.	Sorafenib (BAY 43-9006)
9.	Paclitaxel (Taxol)
10.	Bevacizumab (Avastin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Filtering Surgery
5.	Immunotherapy